Want to see BVNRY full AI Analyst Report?
Top Page
Bavarian Nordic
(OTC:BVNRY)
Select Model
Select Model
Rating:79Outperform
Price Target:
$11.00
▲(24.29% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by strong financial performance—meaningful profitability, solid cash generation, and an exceptionally conservative balance sheet—supported by a positive earnings call with raised 2026 guidance and material Public Preparedness contract momentum. The main offsets are mixed top-line stability and near-term technical overbought risk despite generally positive trend indicators, while valuation appears reasonable on a ~12.7 P/E.
Positive Factors
Raised Guidance and Contract Visibility
Higher guidance and substantial contracted Public Preparedness revenue improve near-term visibility. The BARDA relationship and more than USD 1.2 billion of orders since 2017 support Bavarian Nordic’s established position in government vaccine procurement.
Negative Factors
Lumpy and Mixed Revenue Profile
Revenue remains exposed to episodic government procurement, outbreak-related demand and contract phasing, while the TTM decline indicates limited top-line consistency. This concentration can make capacity planning, earnings forecasting and margin performance less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised Guidance and Contract Visibility
Higher guidance and substantial contracted Public Preparedness revenue improve near-term visibility. The BARDA relationship and more than USD 1.2 billion of orders since 2017 support Bavarian Nordic’s established position in government vaccine procurement.
Read all positive factors
Bavarian Nordic (BVNRY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.28B
Dividend YieldN/A
Average Volume (3M)793.00
Price to Earnings (P/E)12.7
Beta (1Y)1.08
Revenue Growth1.54%
EPS Growth-3.37%
CountryUS
Employees1,795
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.87
Shares Outstanding237,712,550
10 Day Avg. Volume0
30 Day Avg. Volume793
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.15
Price to Sales (P/S)2.49
P/FCF Ratio6.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bavarian Nordic Business Overview & Revenue Model
Company Description
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monke...
How the Company Makes Money
Bavarian Nordic primarily makes money by selling vaccines to governments, public health agencies, and commercial customers, with revenue concentrated in a few key product areas and channels. (1) Public-sector procurement and preparedness: A major ...
Bavarian Nordic Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 21, 2026
Earnings Call Sentiment Positive
The call presented multiple clear positives: solid Q1 revenue (DKK 1.058b), Travel Health growth (14%), successful global rollout of Vimkunya with DKK 41m in Q1, a meaningful BARDA order that completed a long-term freeze-dried contract and led management to raise full-year revenue guidance to DKK 5.5–5.7b and EBITDA margin to ~28%. Management highlighted strong manufacturing performance, secured Public Preparedness revenues (DKK 2.0b secured with DKK 300–500m expected more), and progress on key R&D readouts (Phase II cell-line interim data due later in 2026). The principal negatives are operational timing risks and one-off cash outflows: U.S. regulatory/publication delays (CDC MMWR) creating headwinds for U.S. uptake of Vimkunya, Encepur inventory/shelf-life timing effects that pressured reported Q1 product sales (though market share and market growth are healthy), negative Q1 operating cash flow impacted by milestone payments, and staged pipeline advancement. Overall, positives (raised guidance, contract wins, product rollouts and strong Travel Health metrics) appear to outweigh the manageable and largely timing-related lowlights.Positive Updates
Strong Q1 Revenue and Improved Full-Year Guidance
Total Q1 revenue DKK 1.058 billion (Public Preparedness DKK 294m; Travel Health DKK 721m). Company raised 2026 revenue guidance to DKK 5.5–5.7 billion and increased EBITDA margin target to ~28% (up from 25%).
Negative Updates
U.S. Headwinds for Vimkunya (Chikungunya)
U.S. demand for Vimkunya hindered by delay in CDC MMWR publication of the recommendation and by limited CDC outbreak guidance; some wholesalers are withholding stock until official publication. Management notes publication could take 12–18 months, posing upside/downside risk to the DKK 250m guidance if delayed.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue and Improved Full-Year Guidance
Total Q1 revenue DKK 1.058 billion (Public Preparedness DKK 294m; Travel Health DKK 721m). Company raised 2026 revenue guidance to DKK 5.5–5.7 billion and increased EBITDA margin target to ~28% (up from 25%).
Read all positive updates
Company Guidance
Management raised 2026 guidance: revenue is now expected at DKK 5.5–5.7 billion with an EBITDA margin of ~28% (up from ~25%), driven by an upgraded Public Preparedness outlook of DKK 2.3–2.5 billion (DKK 2.0 billion already secured and an expected additional DKK 300–500 million) while Travel Health guidance remains unchanged (Q1 Travel Health revenue DKK 721 million; Vimkunya full‑year target DKK 250 million). Q1 results underpin the outlook: total revenue DKK 1.058 billion (Public Preparedness DKK 294 million), gross margin 45%, R&D spend DKK 175 million, EBITDA DKK 165 million (16% margin) and cash ≈DKK 2.3 billion at quarter‑end (≈DKK 2.2 billion post share buyback). Capital actions include an ongoing DKK 500 million buyback (≈DKK 350 million executed, ≈DKK 100 million remaining); noteworthy contract metrics include a recent BARDA $97 million order toward the 11.5 million‑dose freeze‑dried program (BN has received >$1.2 billion under that program since 2017). Operational growth signals cited: Travel Health +14% (Q1 excl. discontinued partner revenue), rabies +23% (U.S.) and +29% (Germany), Encepur market +12% with BN +1pp market share, and Vivotif +12% in Q1.Bavarian Nordic Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.66B | 5.93B | 5.72B | 7.06B | 3.15B | 1.90B |
| Gross Profit | 2.81B | 2.81B | 2.82B | 4.53B | 1.70B | 570.32M |
| EBITDA | 2.25B | 1.57B | 1.67B | 2.05B | 84.28M | 35.80M |
| Net Income | 1.18B | 1.32B | 987.98M | 1.48B | -347.38M | -464.77M |
Balance Sheet | ||||||
| Total Assets | 14.12B | 14.95B | 14.41B | 14.35B | 12.39B | 12.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.29B | 3.33B | 2.18B | 1.87B | 2.85B | 3.72B |
| Total Debt | 139.42M | 130.86M | 128.25M | 145.30M | 1.76B | 1.13B |
| Total Liabilities | 1.42B | 2.08B | 3.00B | 4.01B | 5.24B | 4.71B |
| Stockholders Equity | 12.70B | 12.87B | 11.41B | 10.34B | 7.15B | 7.37B |
Cash Flow | ||||||
| Free Cash Flow | 1.36B | 2.42B | 262.19M | 141.80M | -1.16B | -1.42B |
| Operating Cash Flow | 2.34B | 2.62B | 1.95B | 1.12B | 220.05M | -358.50M |
| Investing Cash Flow | -2.13B | -2.39B | -1.87B | -945.56M | -877.40M | -2.88B |
| Financing Cash Flow | -188.16M | -109.97M | 55.77M | 735.83M | 635.82M | 3.54B |
Bavarian Nordic Technical Analysis
Positive
8.85
Price Trends
9.26
Positive
9.62
Negative
9.87
Negative
Market Momentum
0.01
Negative
62.40
Neutral
100.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVNRY, the sentiment is Positive. The current price of 8.85 is below the 20-day moving average (MA) of 9.15, below the 50-day MA of 9.26, and below the 200-day MA of 9.87, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 62.40 is Neutral, neither overbought nor oversold. The STOCH value of 100.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVNRY.
Bavarian Nordic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $2.28B | 12.73 | 9.25% | ― | 1.54% | -3.37% | |
60 Neutral | $8.64B | -14.83 | -69.59% | ― | ― | 1.28% | |
59 Neutral | $6.04B | -13.15 | -43.98% | ― | -100.00% | -33.88% | |
59 Neutral | $9.76B | -36.12 | -21.50% | ― | 134.84% | 6.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.61B | -4.54 | 392.35% | ― | 17.50% | -5.66% |
* Healthcare Sector Average
BVNRY
Bavarian Nordic
9.60
-2.88
-23.07%
RARE
Ultragenyx Pharmaceutical
26.49
-3.21
-10.81%
XENE
Xenon
62.35
24.53
64.86%
IMVT
Immunovant
41.82
26.56
174.05%
KYMR
Kymera Therapeutics
117.39
73.77
169.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.